August 5, 2020
Dear Valued Customer,
In light of the recent directive by the Victorian State Government relating to Stage 4 restrictions due to the COVID-19 pandemic, we advise that our business remains open and committed to providing a minimally interrupted service to the healthcare system. In addition, our hours and methods of operation remain unchanged.
As COVID-19 cases continue in Australia, this letter is intended to help clarify our commitment to continuing supply of Mallinckrodt’s products for the foreseeable future. Mallinckrodt does not currently anticipate any significant disruption to our manufacturing and/or distribution capabilities resulting from the pandemic. Locally, we remain confident that our existing supplies of products together with our forward ordering pattern ensure no likely disruption of supply to our existing customers. However, we continue to monitor this evolving situation.
With this in mind, we are conscious of the potential delays our logistics partners may face whilst in transit largely due to government checkpoints. However, we envisage orders will be fulfilled within a timely manner and we thank you for your understanding as we navigate through these unprecedented times.
On behalf of Mallinckrodt Pharmaceuticals, we thank you for your ongoing support and understanding as we continue to work in partnership with you to get through this pandemic. If you have further questions, I encourage you to reach out to your Mallinckrodt Critical Care Business Manager on 1300 198 565.
Mallinckrodt Pharmaceuticals advises prescribers that any use of a medicine outside its TGA approved indication must be under the TGA Special Access Scheme (SAS) which provides access to non-approved therapeutic goods / indications. Details of the SAS process are provided at https://www.tga.gov.au/form/special-access-scheme.
Steven J. Skorobogaty
General Manager – Australia & New Zealand